ImmuCell Corporation – NASDAQ:ICCC
ImmuCell stock price today
ImmuCell stock price monthly change
ImmuCell stock price quarterly change
ImmuCell stock price yearly change
ImmuCell key metrics
Market Cap | 39.30M |
Enterprise value | 35.37M |
P/E | -15.28 |
EV/Sales | 1.90 |
EV/EBITDA | -46.83 |
Price/Sales | 2.03 |
Price/Book | 1.24 |
PEG ratio | N/A |
EPS | -0.50 |
Revenue | 21.28M |
EBITDA | -1.74M |
Income | -3.89M |
Revenue Q/Q | 110.57% |
Revenue Y/Y | 32.89% |
Profit margin | -12.23% |
Oper. margin | -11.18% |
Gross margin | 41.19% |
EBIT margin | -11.18% |
EBITDA margin | -8.18% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeImmuCell stock price history
ImmuCell stock forecast
ImmuCell financial statements
| Jun 2023 | 3.53M | -1.37M | -39.06% |
|---|---|---|---|
| Sep 2023 | 5.39M | -940K | -17.42% |
| Dec 2023 | 5.09M | -1.14M | -22.37% |
| Mar 2024 | 7.25M | -437.86K | -6.03% |
| Jun 2023 | 44007068 | 17.15M | 38.97% |
|---|---|---|---|
| Sep 2023 | 44545000 | 18.53M | 41.6% |
| Dec 2023 | 43808102 | 18.81M | 42.95% |
| Mar 2024 | 43051048 | 18.41M | 42.77% |
| Jun 2023 | -681.42K | -708.41K | -251.90K |
|---|---|---|---|
| Sep 2023 | -507.75K | -533.25K | 1.57M |
| Dec 2023 | -723.07K | 33.78K | -321.43K |
| Mar 2024 | 418.50K | -70.35K | -366.54K |
ImmuCell alternative data
| Aug 2023 | 67 |
|---|---|
| Sep 2023 | 66 |
| Oct 2023 | 66 |
| Nov 2023 | 66 |
| Dec 2023 | 72 |
| Jan 2024 | 72 |
| Feb 2024 | 72 |
| Mar 2024 | 72 |
| Apr 2024 | 72 |
| May 2024 | 72 |
| Jun 2024 | 74 |
| Jul 2024 | 74 |
ImmuCell other data
| Period | Buy | Sel |
|---|---|---|
| Jun 2022 | 1000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | CUNNINGHAM DAVID director | Common stock $0.10 per value per share | 1,000 | $8 | $8,000 | ||
Purchase | CUNNINGHAM DAVID director | Common Stock, par value $0.10 per share | 2,000 | $4 | $8,000 | ||
Purchase | TOMSCHE DAVID SCOTT director | Common Stock, par value $0.10 per share | 4,600 | $4.28 | $19,688 | ||
Purchase | TOMSCHE DAVID SCOTT director | Common Stock, par value $0.10 per share | 5,130 | $4.98 | $25,547 | ||
Option | BRIGHAM MICHAEL F director, officer.. | Incentive Stock Options (Right to buy) | 47,500 | $1.7 | $80,750 | ||
Option | BRIGHAM MICHAEL F director, officer.. | Common Stock, par value $0.10 per share | 47,500 | $1.7 | $80,750 | ||
Option | CRABB JOSEPH H officer: Vice Pre.. | Common Stock, par value $0.10 per share | 47,500 | $1.7 | $80,750 | ||
Purchase | TOMSCHE DAVID SCOTT director | Common Stock, par value $0.10 per share | 3,000 | $6.67 | $20,010 | ||
Purchase | PESSIN BRIAN L. other: See Explanation of Respo.. | Common Stock | 30,000 | $5.25 | $157,500 | ||
Purchase | PESSIN NORMAN H other: See Explanation of Respo.. | Common Stock | 170,000 | $5.25 | $892,500 |
| Quarter | Transcript |
|---|---|
| Q1 2024 15 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 11 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of ImmuCell stock today?
One share of ImmuCell stock can currently be purchased for approximately $5.9.
-
When is ImmuCell's next earnings date?
Unfortunately, ImmuCell's (ICCC) next earnings date is currently unknown.
-
Does ImmuCell pay dividends?
No, ImmuCell does not pay dividends.
-
How much money does ImmuCell make?
ImmuCell has a market capitalization of 39.30M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 5.9% to 17.47M US dollars.
-
What is ImmuCell's stock symbol?
ImmuCell Corporation is traded on the NASDAQ under the ticker symbol "ICCC".
-
What is ImmuCell's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ImmuCell?
Shares of ImmuCell can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ImmuCell's key executives?
ImmuCell's management team includes the following people:
- Mr. Michael F. Brigham Pres, Chief Executive Officer, Principal Financial Officer, Treasurer, Sec. & Director(age: 64, pay: $354,270)
- Ms. Bobbi Jo Brockmann Vice President of Sales & Marketing and Director(age: 48, pay: $314,800)
- Ms. Elizabeth L. Williams Vice President of Manufacturing Operations(age: 69, pay: $255,650)
- Dr. Joseph H. Crabb Ph.D. Vice President & Chief Scientific Officer(age: 70, pay: $54,980)
-
How many employees does ImmuCell have?
As Jul 2024, ImmuCell employs 74 workers, which is 3% more then previous quarter.
-
When ImmuCell went public?
ImmuCell Corporation is publicly traded company for more then 38 years since IPO on 5 May 1987.
-
What is ImmuCell's official website?
The official website for ImmuCell is immucell.com.
-
Where are ImmuCell's headquarters?
ImmuCell is headquartered at 56 Evergreen Drive, Portland, ME.
-
How can i contact ImmuCell?
ImmuCell's mailing address is 56 Evergreen Drive, Portland, ME and company can be reached via phone at +20 78782770.
ImmuCell company profile:
ImmuCell Corporation
immucell.comNASDAQ
75
Biotechnology
Healthcare
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Portland, ME 04103
CIK: 0000811641
ISIN: US4525253062
CUSIP: 452525306
